International Myeloma Foundation
MYELOMA MINUTE | Up To The Minute News | 1.28.2021
senior patient consults doctor
two ppe wearing medical researchers
Research Continues to Lead the Way
Two myeloma research studies examine disease-monitoring techniques. IMF Chairman Dr. Brian G.M. Durie calls the results “great news.” One study “strengthens our ability to know if patients are truly MRD negative and will have the correspondingly excellent outcomes expected.”
Best of ASH 2020
Watch a Replay of the Best of ASH 2020 Webinar
In this webinar, Dr. Brian G.M. Durie discusses key takeaways from the 2020 American Society of Hematology (ASH) annual conference for patients, caregivers, and others.
understanding blenrep book
BLENREP® (belantamab mafodotin-blmf)
The IMF has a new Understanding-series publication and a Tip Card about Blenrep, an antibody-drug conjugate (ADC) that is the first in a new class of treatments for myeloma. The antibody part of the ADC attracts your body’s own immune system to recognize myeloma cells and attack them.
download button
woman on phone
BMS Foundation Extends Supportive Resources to Patients During the Pandemic
Learn how the BMS Foundation is extending additional support "to help eligible unemployed patients in the U.S. who have lost their health insurance due to the COVID-19 pandemic through the first six months of 2021."
learn more
tiffany richards presenting nlb
Heavily Pretreated Multiple Myeloma and Drugs in Development
We invite you to preview Heavily Pretreated Multiple Myeloma and Drugs in Development, part 3 of the symposium New Strategies for Multiple Myeloma Care: Case Studies for Nurses. Highly experienced nurses share their expertise through a real-life patient case study of Carl, a patient who has received several multiple myeloma therapies over his 10-year history with the disease. Our faculty will discuss clinical trial participation and drugs in development. You can also watch the symposium in its entirety and download free slides!
doctor is talking to patient
IMF Comments on Most Favored Nations Model
On January 20, 2021, the International Myeloma Foundation sent a letter to the Centers for Medicare and Medicaid Services objecting to the Interim Final Rule with Comment Period entitled “Most Favored Nations Model” (MFN). The IMF believes myeloma patients could be disproportionately impacted by the proposal. Learn why on this page, and click the link below to read the letter in full.
miles for myeloma virtual logo
The 13th Annual Miles for Myeloma 5K Run/Walk Goes Virtual Once Again
The 13th Annual Miles for Myeloma 5K Run/Walk is going virtual once again! This exciting style of race is just as fun and competitive as it was in person, just a whole lot safer. This 5K Run/Walk will Redefine Being Together. Learn how you can take part individually or by forming a virtual team at the link below.
register button
ask doctor durie video image
#ASKDRDURIE | Dr. Durie's Weekly Web Video Series
This Week’s Question:

COVID-19 FAQ #7: Is it safe for myeloma patients to take walks?
Watch Now
Clinical Trials
OCEAN Trial (Fully Accrued)

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)
Search the Myeloma Matrix 2.0

Smart Patients: Join the Conversation
Upcoming Events
Learn More
Charity Rumble: Myelo-no-more!

Watch the Replay
“IMWG Conference Series: ASH 2020”

Watch the Replay
“Living Well with Myeloma” Webinar

Watch the Replay
IMF Patient & Family Webinar

Learn More
Winter Challenge

Click here to see all events

We Thank Our Sponsors:

Amgen; Bristol-Myers Squibb; Genentech; GSK; Karyopharm Therapeutics; Oncopeptides, Inc.;
Sanofi-Genzyme; and Takeda Oncology
We also thank individuals like you for your continued support!
Subscribe Button@2x.jpg
Join the conversation at The International Myeloma Foundation
Facebook Facebook: /Myeloma  |  Twitter Twitter @IMFMyeloma  |  Instagram Instagram @IMFmyeloma
This email was sent by:
The International Myeloma Foundation
12650 Riverside Drive, Suite 206
North Hollywood, CA 91607-3421
Connect with the IMF InfoLine
We respect your privacy and your preferences for communications of this nature.
Home  •  Unsubscribe  •  Privacy Policy
View as web page